|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
TUD-PEMAZA-068 |
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
|
 |
 |
|
TUD-RELA02-048 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®)
|
|
|
|
|
TUD-RELA02-048 |
Sonstige Studien
[-]
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®)
|
 |
|
|
|
U31287-A-U203 DAIICHI |
Kopf-Hals-Tumore
[C00-C14, C30.-,C33]
|
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study
of Patritumab (U3-1287) in Combination with Cetuximab plus
Platinum-Based Therapy in First Line Setting in Subjects with
Recurrent or Metastatic Squamous Cell Carcinoma of the Head
and Neck
|
 |
|
|
|
Vaccibody VB N-01 |
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
|
An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
|
|
|
|
|
Varianz |
Magentumor
[]
|
Vorhersage von Ansprechen oder Resistenz durch Identifizierung von Biomarkern beim Adenokarzinom des Magens und des gastroösophagealen Übergangs innerhalb einer nicht-interventionellen Studie und zielgerichteter Therapie mit Trastuzumab
|
|
|
|
|
VB N-01 |
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
Sonst. urogenitale Tumore z.B. Blase,Niere
[]
Krebserkrankungen der Haut
[]
Lungenkrebs
[]
Sonstige Tumore
[]
|
An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint Blockade - Melanom Kohorte geschlossen
Z-Nr.: 347
TrackCell Tablets located in III Med Studiensekretariat
Second Pharmajet handed over to Urologie Department on 26Sep2019
|
|
|
|
|
Venezia-CIP-001 |
Bösartige Neubildung der Cervix uteri
[C53.-]
Gynäkologische Tumore
[]
|
Multi-center prospective observational Clinical Follow-Up study Advanced Gynecological Applicator - Venezia Configuration
|
 |
|
|
|
VesPa |
Schwindel und Taumel
[R42]
|
Therapie der Vestibularisparoxysmie mit Carbamazepin: eine prospektive randomisierte Placebo-kontrollierte doppelblinde multizentrische Studie
|
|
|
|
|
VIOLETTE |
Brustkrebs
[]
|
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes
(including BRCA1/2) (VIOLETTE)
|
|
|
|
|
Vitamin D Vertigo |
Schwindel und Taumel
[R42]
|
Sekundärprophylaktische Behandlung des benignen peripheren paroxysmalen Lagerungsschwindels (BPPV) mit Vitamin D
|
|
|
|
|
VOLFI |
Bösartige Neubildung des Kolons
[C18.-]
Krebs des Verdauungstrakts
[]
Tumor des Dickdarms / Mastdarms
[]
|
An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type (AIO KRK 0109)
|
|
|
|
|
VONES100 |
Sonstige Tumore
[]
|
Verlauf und Outcome-Korrelation der glialen Proteine S100? und Neuronen-spezifischer Enolase (NSE) im Blut bei der Bestrahlung von Hirnmetastasen (VONES100)
|
|
|
|
|
WA42380 (COVACTA) |
Infektiologie
[-]
|
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
|
|
|
|
|
WO29636 |
Sonstige Tumore
[]
|
a Phase III, open-Label, multicenter, randomized study of ATEZOLIZUMAB (ANTI-L1 Antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high-risk muscle-invasive bladder cancer after cystectomy
|
|
|
|
|
WOPP |
Sonstiger Spontanpneumothorax
[J93.1]
|
Pulmonary wedge resection plus parietal pleurectomy (WRPP) versus parietal pleurectomy (PP) for the treatment of recurrent primary pneumothorax (Prospektiv-randomisierte multizentrische klinische Studie zum Vergleich zweier etablierter Operationsmethoden)
|
|
|
|
|
WX60-004 |
Bösartige Neubildung des Pankreas
[C25.-]
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy
|
|
|
|
|
Xenon |
Bösartige Neubildung am Rektosigmoid, Übergang
[C19]
Krebs des Verdauungstrakts
[]
Tumor des Dickdarms / Mastdarms
[]
|
Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Studie der Phase III zur Beurteilung der Wirksamkeit von Xaliproden bei Patienten mit Oxaliplatin-induzierter peripherer sensorischer Neuropathie (PSN) nach unterstützender Chemotherapie wegen Dickdarmkrebs
|
|
|
|
|
Xolair (Omalizumab) |
Sonstige Studien
[-]
Idiopathische Urtikaria
[L50.1]
|
A PHASE III; Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Evaluate the efficacy and safety of XOLAIR (Omalizumab) in Patients with chronic Idiopathic Urticaria (CIU) Who remain Symptomatic Despite Antihistamine Treatment (H1)
|
|
|
|
|
Y-IMAGE |
Bösartige Neubildung sonstigen Bindegewebes und anderer Weichteilgewebe
[C49.-]
Sarkome (Knochen- und Weichteilkrebs)
[C40-C41]
|
Y-IMAGE: a non-interventional multicenter, prospective study to evaluate treatment outcome as assessed in routine clinical practice on patients with advanced soft tissue sarcoma treated with trabectedin according to the Summary of Product Characteristics (SmPC)
|
|
|
|
|
YonSar |
Bösartige Neubildung sonstigen Bindegewebes und anderer Weichteilgewebe
[C49.-]
Sarkome (Knochen- und Weichteilkrebs)
[C40-C41]
|
Non-interventional study to investigate efficacy and safety of Trabectedin (Yondelis®) in patients with advanced soft tissue sarcoma
|
|
|
|
|
ZILVERPASS |
Atherosklerose der Extremitätenarterien
[I70.2-]
|
Eine prospektive, multizentrische, randomisierte Studie zur Bewertung der Implantation Medikament-freisetzenden Stents (Cook Zilver PTX) im Vergleich zu einer Bypass-Operation bei Behandlung der femoropoplitealen TASC C & D Läsionen
|
|
|
|
|
ZUMA-3 |
Akute lymphatische Leukämie [ALL]
[C91.0-]
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
|
|
|
